Arirang Insight.

What Happened

The Ministry of Food and Drug Safety (MFDS), Korea's medicines and medical-device regulator, has set a target to run "the world's fastest" product approval system. In its 2026 administrative plan, reported by Minister Oh Yu-kyoung, MFDS said it will cut review periods that ran as long as 420 days for biosimilars down to 240 days, applying the target across new drugs and medical devices.

The mechanics are procedural, not cosmetic. MFDS plans deeper pre-submission reviews to improve data completeness, parallel review of assessment items rather than sequential ones, dedicated review teams, and more face-to-face consultations. It will add an "AI Approval and Review Support System" to summarise and translate submitted data and draft review documents.

Two structural changes matter most for device makers. MFDS will shift to a negative-list change-approval system, requiring pre-approval only for changes that affect a device's safety or performance, with other modifications managed by the company. And it will introduce self-certification of performance for digital medical and health-support devices.

This sits on top of a separate January 2026 reform, the "Market Immediate Entry Medical Technology" system, which lets devices that clear MFDS's reinforced clinical evaluation skip the separate New Medical Technology Assessment and reach hospitals in as little as 80 days, down from up to 490, across 199 device categories.

Why It Matters

Korea has long been a procedure-heavy market with two distinct bottlenecks: MFDS approval, then a market-access assessment before clinical use. Korea is now compressing both ends at once.

For Swiss and European companies, the negative-list change system is the quiet headline. Iterative digital and AI-enabled devices previously risked re-approval on minor updates; limiting pre-approval to safety- or performance-relevant changes lowers a real lifecycle cost. Self-certification for digital-device performance removes another familiar friction for SaMD firms.

The trade-off is evidence. The fast lane is reserved for devices that pass an "internationally enhanced clinical evaluation." Faster timelines raise, not lower, the bar on the clinical package, and European data may need bridging for Korean review.

What to Watch

Whether the 240-day figure actually holds for medical devices. The headline number comes from the biosimilar track, and device reviews may compress more slowly.

How "changes affecting safety or performance" are defined in practice. That definition decides how much lifecycle burden genuinely falls for AI and software devices.

Whether the digital self-certification route is recognised only by MFDS, or also carries weight with payers. Approval speed means little without a matching reimbursement path through HIRA.

What Happened

South Korea is dismantling a long-standing feature of its hospital-supply market: the affiliated intermediary. Most Korean hospitals buy medical devices and consumables not directly from manufacturers but through a single "middle distribution" company. Many of those intermediaries are owned or controlled by the hospital's director or its founding medical foundation.

At the end of December 2025, the National Assembly amended the Medical Devices Act to ban transactions between a hospital and an intermediary tied to it by a special relationship. The trigger points are concrete: ownership of 50% or more of the intermediary's shares, control by a relative within the second degree of kinship (for example, a director's spouse), or dominant influence over the company's management. The Ministry of Health and Welfare (MOHW), which oversees the sector, made cleaning up device distribution a national policy priority.

Hospitals are already moving. The Asan Foundation is selling its 51% stake in Medigood Partners, the intermediary that supplies Asan Medical Center. Seoul St. Mary's and Severance have unwound their equity ties. Of the "Big 5" hospitals, Seoul National University Hospital and Samsung Medical Center hold no majority stakes and are unaffected. Most large hospitals outside the Big 5 are expected to follow, and private-equity buyers are circling the assets that come loose.

Why It Matters

For European device makers, the affiliated intermediary has been an invisible gatekeeper. Where a hospital owned its distributor, the channel was effectively closed: pricing, product choice and access ran through a captive middleman aligned with the hospital, not the manufacturer. That structure has frustrated foreign entrants for years and is one reason Korea rewards relationship-driven selling.

Severing these ties does two things. It loosens a barrier that favoured incumbents, and it puts a wave of newly independent distributors — some soon backed by private equity — into play as potential partners. A European manufacturer that has struggled to place products through a hospital-owned intermediary may find a more neutral, commercially motivated channel emerging in its place.

What to Watch

Watch which intermediaries change hands and who buys them. Private-equity ownership tends to professionalise a distributor and make it more open to new suppliers and clearer terms.

Watch the transition timeline. Hospitals are divesting ahead of the ban's effective date, so the channel will look different across 2026 and into 2027 — a window to reassess distribution partners.

Watch for workarounds. Korean commentators already warn that some hospitals may restructure ownership to stay under the thresholds rather than genuinely open their procurement.

What Happened

On 7 September, Dong-A ST, a Korean drugmaker with a growing digital-health arm, said it had signed a supply agreement with Schiller Asia Pacific to distribute its wearable patient-monitoring platform, HiCardi, across six Asia-Pacific markets: Thailand, Malaysia, the Philippines, Taiwan, Australia and Singapore. Schiller Asia Pacific will act as master distributor, selling through local partners in each country.

The counterparty is the point. Schiller Asia Pacific is the regional arm of Schiller AG, a Swiss medical-device maker founded in 1974 and known for electrocardiogram (ECG) systems, defibrillators and patient monitors. HiCardi, developed by Korean company MeZoo and marketed by Dong-A ST, is a lightweight patch that tracks ECG, heart rate, respiratory rate, skin temperature and oxygen saturation, then streams the data for remote monitoring. It is used in more than 800 Korean hospitals. The deal follows an earlier push into Brazil and Latin America.

Why It Matters

For European MedTech, the signal is not the Asian geography but the Swiss name on the contract. Schiller is a recognised European cardiology and monitoring brand. Choosing to carry a Korean wearable, rather than build or buy its own, is a quiet endorsement of MeZoo's technology and a reminder that Korean ambulatory remote-monitoring firms have reached a quality bar Western incumbents will now distribute.

It also hints at what could come next. MeZoo already holds a CE mark and counts the European Union among nine markets where it has regulatory clearance. A distribution relationship that begins in Asia can migrate to Europe once a partner grows comfortable with a product. European remote-monitoring and cardiac-diagnostics companies should read this as competitor intelligence: the Korean patch they may soon meet in a tender could arrive through an established European channel, not cold.

This is primarily an Asia-Pacific commercial move. The European relevance is indirect, but real.

What to Watch

Whether the Schiller relationship extends beyond Asia. Schiller's core market is Europe; if HiCardi enters its European catalogue, a low-cost Korean patch gains instant reach into European hospitals.

MeZoo's European regulatory and reimbursement progress. A CE mark opens the door, but ward-based continuous monitoring becomes a business only once hospitals can bill for it. Watch for pilots in Germany, France or the Nordics.

Consolidation in cardiac monitoring. The Brazilian partner in Dong-A ST's earlier HiCardi deal, CARDIOS, belongs to Italy's Cardioline group, a sign that remote-diagnostics distribution is consolidating across borders and that Korean device makers are plugging into these networks rather than building their own.

What Happened

Mediwhale, a Seoul-based medical AI company founded in 2016, is moving its retinal cardiovascular AI into Europe through an established local partner. In February 2026, iCare — the ophthalmic-diagnostics brand of Finland's Revenio Group, listed on Nasdaq Helsinki — signed a memorandum of understanding to integrate Mediwhale's Dr. Noon CVD software into its DRSplus fundus camera and iCare Screening Solution. The combined system lets clinicians estimate cardiovascular risk from a routine retinal photograph, without blood tests, radiation or a cardiac CT.

Dr. Noon CVD analyses images of the retina — the one place where blood vessels can be viewed directly — to predict cardiovascular and chronic kidney disease risk. Mediwhale says its accuracy is comparable to the coronary artery calcium score derived from a CT scan. The software is already used in more than 170 hospitals worldwide, including Korea's Yonsei University Health System. In April 2026 the company raised a 20 billion won (about $13 million) Series C led by Premier Partners, taking total funding to roughly $34 million, and said it is preparing a Kosdaq listing in the first half of 2027.

Why It Matters

For European MedTech, the signal is who did the choosing. Revenio is not a startup; it is a profitable European eye-care specialist, with 2024 net sales of 103.5 million euros, that sells screening hardware across the region. Its decision to embed a Korean algorithm rather than build or buy a European one is a competitive data point for any European firm in ophthalmic imaging, cardiovascular diagnostics or preventive screening.

The deeper shift is the retinal exam becoming a gateway to systemic health. If a low-cost, radiation-free fundus photograph can flag cardiovascular and kidney risk, it competes with parts of the cardiac-CT and lab-based risk-scoring pathways that European diagnostics companies serve today. Switzerland's strengths in cardiology, precision prevention and diagnostics sit directly in that path. Mediwhale is best read as a scoutable partner, a distribution opportunity for firms with European hospital channels, or an emerging competitor whose technology a European incumbent has already validated.

What to Watch

Whether the iCare partnership moves from MoU to a shipped product with CE-covered clinical claims. Integration announcements are common; reimbursed clinical use is the harder test.

How European payers and guideline bodies treat retina-based cardiovascular risk. Adoption will hinge on evidence accepted in Europe, not Korea.

Mediwhale's regulatory path. It is pursuing US FDA De Novo clearance and a 2027 Kosdaq listing, both of which would strengthen a company that a European partner is already building into its platform.

What Happened

Sky Labs, the Korean digital-health company behind a ring-shaped cuffless blood-pressure monitor, listed on Kosdaq — Korea's tech-heavy secondary exchange — on 4 September. The stock opened sharply higher, trading around 27,150 won on the first morning, up about 171% from an initial public offering price of 10,000 won a share. The company sold 2 million new shares at that price, raising roughly 20 billion won (about $15 million) to fund research and global expansion.

The listing closes a loop the company opened in August. Its flagship device, CART BP Pro, is a finger-worn ring that records blood pressure continuously over 24 hours, replacing the inflatable arm cuff. By June 2026 it was in use at around 2,000 Korean hospitals and clinics, including all five of the country's largest hospitals. The device is reimbursed under national health insurance and listed in the Korean Society of Hypertension's 2026 guidelines. Overseas sales already accounted for 52% of first-half revenue.

Why It Matters

For European MedTech, the signal is not the ring itself but the balance sheet behind it. A Korean remote-monitoring firm now has fresh capital, a strong market debut and majority-overseas revenue — and it is pointing that firepower at Europe. Sky Labs holds CE-MDR certification and UK MHRA registration, and in late August signed a supply deal with Germany's IEM GmbH to move its clinic device into UK and European hospitals. It is also working with Omron Healthcare and Otsuka on European and Japanese expansion.

That combination — clinical validation at home, an incumbent European channel, and now public-market funding — is what turns a promising device into a durable competitor. European makers of ambulatory and remote blood-pressure monitoring should treat Sky Labs as a funded rival, a possible partner, or an acquisition target, not a distant startup. The stronger reading is strategic: the listing frames Sky Labs less as a device maker than as a medical-data platform, using continuous vital-sign data for clinical research and AI.

What to Watch

Whether the IEM rollout converts into hospital adoption and local reimbursement in the UK and Germany — the step where Korean health-tech firms most often stall in Europe.

How the Omron and Otsuka relationships evolve. Deeper co-development or distribution would widen European reach quickly.

The platform pivot. Sky Labs' CART NET data services and multi-vital devices, CART O2 and CART VITAL, signal ambitions beyond blood pressure, into real-world evidence and trials that European pharma and contract research organisations may find relevant.